drugset / Trial / NCT00583063

Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers

NCT00583063

Phase 0 Completed 23 enrolled University of Chicago Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Determine the pharmacokinetic interactions between rapamycin and sunitinib in patients with advanced solid tumors.

Timeline

Start
2007-10
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 4 mg Oral
Subject Sunitinib Small molecule 25 mg Oral

Indications